Sanofi's Tzield Gains FDA Approval for Type 1 Diabetes Therapy

Sanofi's Tzield (teplizumab-mzwv) has received accelerated approval from the US FDA. The approval applies to children aged eight to 17 years recently diagnosed with stage 3 type 1 diabetes (T1D). Tzield aims to delay the decline in natural insulin production. This is the first therapy of its kind to target the autoimmune progression of stage 3 T1D.

The decision is based on the PROTECT phase 3 study and additional data from other clinical programs involving over 900 patients. Tzield is a monoclonal antibody, not suitable for non-autoimmune dysglycemic conditions. The FDA’s accelerated approval means continued use will require further verification through confirmatory studies.

The approval adds momentum to Tzield's previous endorsements in various global jurisdictions for stage 2 T1D. The BETA-PRESERVE phase 3 study is ongoing to substantiate the clinical benefits of this treatment.